KAZ954A
Total Payments
$196,317
Transactions
6
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $196,317 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $196,317 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I/IB, OPEN-LABEL, MULTI-CENTER, STUDY OF KAZ954 AS A SINGLE AGENT AND IN COMBINATION WITH SPARTALIZUMAB, NZV930 AND NIR178 IN PATIENTS WITH ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $196,317 | 0 |
Top Doctors Receiving Payments for KAZ954A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $196,317 | 6 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $196,317
Product Information
- Type Drug
- Total Payments $196,317
- Total Doctors 0
- Transactions 6
About KAZ954A
KAZ954A is a drug associated with $196,317 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $196,317 was paid across 6 transactions to 0 doctors.
The most common payment nature for KAZ954A is "Unspecified" ($196,317, 100.0% of total).
KAZ954A is associated with 1 research study, including "A PHASE I/IB, OPEN-LABEL, MULTI-CENTER, STUDY OF KAZ954 AS A SINGLE AGENT AND IN COMBINATION WITH SPARTALIZUMAB, NZV930 AND NIR178 IN PATIENTS WITH ADVANCED SOLID TUMORS" ($196,317).